Cost Access Issues Result In Slow Adoption Of BiDil For Blacks With Heart Problems Wall Street Journal Reports
BiDil the first drug approved by FDA for use in a single racial group is reaching about 1% of the 750000 U.S. blacks with congestive heart failure for whom it is intended in part because of its high cost the availability of an off-label generic alternative and restrictions under the Medicare prescription drug benefit the Wall Street Journal reports. [click link for full article]
posted by Smile Community @ 12:00 AM
0 Comments:
Post a Comment
<< Home